| | | 股票代码：600272 股票简称：开开实业 编号：2025-053 900943 开开 B 股 上海开开实业股份有限公司 拟续聘 2025 年度财务报表审计和内部控制审计 会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：上会会计师事务所(特殊普通合伙)。 上海开开实业股份有限公司（以下简称"公司"）第十届董事会第二 十八次会议审议通过了《公司拟续聘 2025 年度财务报表审计和内部控制 审计会计师事务所的议案》，拟续聘上会会计师事务所(特殊普通合伙（) 以 下简称"上会"）为公司 2025 年度财务报表审计和内部控制审计机构， 聘期一年，审计费用总额不超过 85 万元（其中内控审计费用 10 万元）。 公司董事会授权公司总经理室办理签订 2025 年度聘用合同等相关事宜。 上述议案尚需提交公司 2025 年第一次临时股东大会审议。现将具体情况 公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 2、人员信息 截至 2024 年末， ...

股票代码：600272 股票简称：开开实业 编号：2025—055 900943 开开 B 股 上海开开实业股份有限公司 关于使用闲置自有资金购买银行理财产品的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 委托理财受托方：上海银行股份有限公司静安支行（以下简称"上 海银行"）； 委托理财金额：人民币4,000万元。 委托理财产品类型：结构性存款； 委托理财期限：188天； 履行的审议程序：2025年4月28日上海开开实业股份有限公司（以下 简称： "公司"）召开第十届董事会第二十五次会议，以9票同意、0票反 对、0票弃权的表决结果，审议通过了《关于董事会授权购买低风险理财产 品的议案》，授权公司总经理室在2025年4月至2026年4月期间，阶段性的 继续利用短期闲置资金总金额不超过人民币1.8亿元，购买低风险理财产品。 在上述额度内资金可以滚动使用。在资金额度的使用期限内任一时点的交 易金额（含前述投资的收益进行再投资的相关金额）不超过该投资额度。 本议案无需提交股东大会审议。 特别风险提示：公司本 ...

| 股票代码：600272 | 股票简称：开开实业 | | | 编号：2025—054 | | --- | --- | --- | --- | --- | | 900943 | | 开开 | 股 B | | 上海开开实业股份有限公司 2025 年半年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海开开实业股份有限公司（以下简称"公司"）根据《上海证 券交易所上市公司自律监管指引第 3 号—行业信息披露》附件《第四 号—零售》《关于做好主板上市公司 2025 年半年度报告披露工作的 重要提醒》等有关规定的要求，现将公司 2025 年半年度主要经营数 据披露如下： 一、报告期内门店变动情况 2) 服装板块 3) 其他 2、主营业务分地区 单位：万元 币种：人民币 分行业 营业收入 营业收入比 同期增减(%) 营业成本 营业成本比 同期增减(%) 毛利率 (%) 毛利率比同期增减 (%) 批发业 40,297.08 25.11 34,674.66 31.81 13.95 减少 4.38 个百分点 零售业 ...

Core Viewpoint - The company reported a revenue increase of 10.95% year-on-year for the first half of 2025, but net profit decreased significantly by 61.94%, indicating challenges in the market despite revenue growth [1] Financial Performance - The company achieved a revenue of 543 million yuan, an increase of 53.62 million yuan compared to the same period last year, reflecting a growth rate of 10.95% [1] - Net profit attributable to shareholders was 11.801 million yuan, down 61.94% year-on-year [1] - The net profit after excluding non-recurring gains and losses was 3.0084 million yuan, a decrease of 8.67% year-on-year [1] - Basic earnings per share were reported at 0.049 yuan [1] Business Segments - The company's "big health" strategic transformation has led to steady growth in the pharmaceutical sector, with the SPD project generating approximately 290 million yuan in revenue, a remarkable year-on-year increase of 52% [1] - The domestic consumption market adjustment has resulted in more rational consumer spending on high-end health products, leading to a decline in sales scale and gross profit for these non-essential items [1] - The apparel segment, while focusing on quality improvement and efficiency, faced challenges due to market conditions and changing consumer sentiment, resulting in decreased sales scale and profitability during the reporting period [1]

开开实业公告，2025年上半年营业收入5.43亿元，同比增长10.95%。净利润1180.1万元，同比下降 61.94%。 ...

Market Overview - The pharmaceutical commercial sector increased by 0.27% on August 21, with Guofang Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3771.1, up 0.13%, while the Shenzhen Component Index closed at 11919.76, down 0.06% [1] Stock Performance - Guofang Co., Ltd. (600538) closed at 6.41, up 1.91% with a trading volume of 315,600 shares and a transaction value of 202 million yuan [1] - Nanjing Pharmaceutical (600713) closed at 5.39, up 1.70% with a trading volume of 181,000 shares and a transaction value of 96.97 million yuan [1] - Shanghai Pharmaceuticals (601607) closed at 19.20, up 0.95% with a trading volume of 173,600 shares and a transaction value of 333 million yuan [1] - Yifeng Pharmacy (603939) closed at 24.49, up 0.91% with a trading volume of 88,100 shares and a transaction value of 215 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 277 million yuan from institutional investors, while retail investors saw a net inflow of 293 million yuan [2] - The data indicates that institutional investors are withdrawing capital, while retail investors are increasing their investments in the sector [2] Individual Stock Capital Flow - Nanjing Pharmaceutical saw a net inflow of 16.81 million yuan from institutional investors, while retail investors had a net outflow of 4.14 million yuan [3] - Yifeng Pharmacy experienced a net inflow of 15.49 million yuan from institutional investors, with a net outflow of 23.62 million yuan from retail investors [3] - China National Pharmaceutical (600056) had a net inflow of 8.93 million yuan from institutional investors, while retail investors had a negligible net inflow of 0.12 million yuan [3]

Market Overview - The pharmaceutical commercial sector increased by 0.05% on August 20, with Yifeng Pharmacy leading the gains [1] - The Shanghai Composite Index closed at 3766.21, up 1.04%, while the Shenzhen Component Index closed at 11926.74, up 0.89% [1] Stock Performance - Yifeng Pharmacy (603939) closed at 24.27, up 0.87% with a trading volume of 58,700 shares and a turnover of 141 million yuan [1] - Other notable performers include: - Liuyuan Group (603368) at 18.64, up 0.76% [1] - China National Pharmaceutical Group (600511) at 30.01, up 0.60% [1] - Shanghai Pharmaceuticals (601607) at 19.02, up 0.58% [1] - Nanjing Pharmaceutical (600713) at 5.30, up 0.57% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 377 million yuan from institutional investors, while retail investors saw a net inflow of 367 million yuan [2] - Notable capital flows include: - Yifeng Pharmacy had a net outflow of 9.79 million yuan from institutional investors [3] - Heavy Drug Holdings (000950) saw a net inflow of 7.45 million yuan from institutional investors [3] - Drug Easy Purchase (300937) had a net inflow of 3.82 million yuan from institutional investors [3]

Market Performance - The primary economic sector increased by 0.97% compared to the previous trading day, with Yaowang Technology leading the gains [1] - The Shanghai Composite Index closed at 3728.03, up 0.85%, while the Shenzhen Component Index closed at 11835.57, up 1.73% [1] Individual Stock Performance - Yaowang Technology (002291) closed at 6.70, rising by 3.40% with a trading volume of 597,700 shares and a transaction value of approximately 67.6 million [1] - Shanghai Phoenix (600679) closed at 13.23, up 2.64%, with a trading volume of 148,500 shares and a transaction value of approximately 197 million [1] - Dafeng Industrial (603081) closed at 13.78, increasing by 1.92%, with a trading volume of 364,800 shares and a transaction value of approximately 509 million [1] - Other notable performers include Liansheng Co. (600826) with a 1.55% increase and a transaction value of approximately 274 million [1] Capital Flow Analysis - The primary economic sector experienced a net outflow of 55.36 million from institutional investors, while retail investors saw a net inflow of 30.52 million [2] - The net inflow from speculative funds was 24.84 million, indicating a mixed sentiment among different investor types [2] Detailed Capital Flow for Selected Stocks - Liansheng Co. (600826) had a net inflow of 15 million from institutional investors but a net outflow of 9.83 million from speculative funds [3] - Yaowang Technology (002291) saw a net inflow of 11.03 million from institutional investors, while speculative funds experienced a net outflow of 21.64 million [3] - Liyade (300296) had a net inflow of 7.75 million from institutional investors, with a significant net inflow of 31.19 million from speculative funds [3]

Market Performance - The pharmaceutical commercial sector increased by 0.27% on August 15, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 3696.77, up 0.83%, while the Shenzhen Component Index closed at 11634.67, up 1.6% [1] Individual Stock Performance - RunDa Medical (603108) closed at 18.15, up 2.02%, with a trading volume of 228,200 shares and a transaction value of 410 million yuan [1] - Other notable performers included Huaren Health (301408) at 14.77, up 1.79%, and Yixin Pharmacy (002727) at 14.97, up 1.70% [1] - Conversely, Seer Medical (603716) saw a decline of 3.69%, closing at 28.41, with a trading volume of 358,300 shares and a transaction value of 1.017 billion yuan [2] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 199 million yuan from institutional investors, while retail investors saw a net inflow of 162 million yuan [2] - The data indicates that retail investors are more active in the sector compared to institutional investors [2] Detailed Capital Flow for Selected Stocks - For 瑞康医药 (002589), the net inflow from institutional investors was 15.82 million yuan, while retail investors had a net outflow of 18.36 million yuan [3] - RunDa Medical (603108) had a net inflow of 7.52 million yuan from institutional investors, but also saw outflows from retail investors [3] - The overall trend shows that while some stocks attract institutional interest, retail investors are more likely to withdraw their investments [3]

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.01% on August 13, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with the following notable movements: - Seli Medical (603716) rose by 6.55% to a closing price of 31.09, with a trading volume of 556,200 shares and a transaction value of 1.671 billion [1] - Guofa Co. (600538) increased by 1.75% to 6.38, with a trading volume of 129,600 shares [1] - Huaren Health (301408) fell by 1.76% to 15.11, with a trading volume of 179,600 shares and a transaction value of 271 million [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 33.73 million from institutional investors, while retail investors experienced a net outflow of 42.05 million [2] - Notable capital flows for specific stocks included: - Seli Medical had a net inflow of 10.9 million from institutional investors, while retail investors saw a net outflow of 2.46 million [3] - Yiyang Pharmaceutical (301015) had a net inflow of 6.29 million from institutional investors, but retail investors faced a net outflow of 31.02 million [3]